N/A
Completed N=20
Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet
Ischemia
Source: ClinicalTrials.gov NCT01072669 ↗
Enrolled (actual)
20
Serious AEs
0.0%
Results posted
May 2013
Primary outcomePrimary: Digital Micro-vascular Flow — .11; .18; -.01; -.06 perfusion unit
Summary
The purpose of this study is to investigate the effectiveness of a drug called ambrisentan, approved by the FDA for use in pulmonary hypertension (a condition where there is increased pressure in the right side of the heart) in scleroderma patients, to see if this medicine may be beneficial in relieving and/or preventing Raynaud's flares in you and other patients like you. This medicine may have some short-term and long-term benefits in persons with scleroderma
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Digital Micro-vascular Flow |
.11; .18; -.01; -.06 | — |
Eligibility Criteria
Inclusion Criteria
- Subjects should have limited scleroderma with disease duration 7 years
Data sourced from ClinicalTrials.gov (NCT01072669). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.